Navigation Links
Hemophilia Pipeline Overview - Once-a-week prophylaxis may soon become a reality
Date:12/13/2012

recombinant compounds can only gain significant market share by either addressing the lack of long-acting recombinant factor IX therapeutics or by addressing the need for more competitively priced recombinant products.

Economy of scale plays a role when producing a biologic compound cost-effectively and established companies will have an advantage in this area; having the right infrastructure, production facilities, marketing channels, and sales force are important factors that will determine whether a company can successfully enter the hemophilia market.

Datamonitor's up to date key pipeline hemophilia A and B therapeutics profiles includes the latest clinical data and industry developments.Understand the most pressing unmet needs in hemophilia and how current pipeline products can gain significant market share by addressing them.Compare pipeline products with current gold-standard treatments and assess what they will have to do to deliver growth.

OVERVIEW

Catalyst

Summary

Clinical Pipeline Overview

A handful of key players dominate the market

Gene therapy looks hopeful but market entry is still not predicted for this decade

Current Gold-Standard Product Profiles

Kogenate FS (FVIII recombinant; Bayer): the gold-standard hemophilia A therapy

BeneFIX (FIX recombinant; Pfizer): the gold-standard hemophilia B therapy

Target product profile versus current level of attainment

Key Factor VIII Pipeline Products

NN7008 (turoctocog alfa; Novo Nordisk)

BIIB 031 (rFVIIIFc; Biogen Idec)

NN7088 (rFVIII, glycopegylated; Novo Nordisk)

BAY-94-9027 (recombinant PEGylated factor VIII; Bayer)

Clinical and commercial attractiveness for key hemophilia A pipeline products

Key Factor IX Pipeline Products

BAX 326 (
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
2. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
6. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
7. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
8. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
9. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: ... injectable drug delivery systems, today announced that its Chairman ... present at the Piper Jaffray 26th Annual Healthcare Conference ... EST on Tuesday, December 2, 2014. ... as a "live" listen only Webcast. To listen, please ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SPRING, Md., June 24, 2011 Breast cancer patients and ... 7:00 am outside of the Federal Drug Administration (FDA).  At ... anti-cancer drug Avastin from the approved medication list for treatment ... in 2008 for use to treat breast cancer. ...
... June 24, 2011 SweetSpot Diabetes Care, Inc. ... as a Medical Device Data System (MDDS) with the FDA ... Diabetes Association Scientific Sessions meeting in San Diego, CA. ... control the transfer of data from patient diabetes devices to ...
Cached Medicine Technology:Breast Cancer Patients and Families Stand Up To FDA 2
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... 27, 2014 Dr. Ronald Receveur, who has ... a few oral health tips before patients dig into the ... and New Albany affordable cosmetic dentistry, and his ... starch and sugar. While the staff wishes everyone a happy ... for how patients can enjoy a feast that is also ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... 27, 2014 Allowing children to help with ... school, helps give children responsibility, ownership, boosts self-esteem, and above ... , Now, the real question is, how do you encourage ... According to a study published by Child Development Journal, there ... dramatic effect on a child’s willingness to lend a hand. ...
(Date:11/27/2014)... November 27, 2014 "The uglier, the better," ... of December is full of laughter as we enjoy the ... by making a sweater from scratch. " It was a ... and if that weren't ridiculous enough, the Christmas balls were ... , For those interested in participating this year, it's simple ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
... By Randy Dotinga HealthDay Reporter , ... that they,ve successfully implanted "biosynthetic" corneas in 10 patients, ... those with cornea-related vision problems. "The patients, own ... overall improvement in vision," said study co-author May Griffith. ...
... it has filed an Investigational New Drug (IND) application ... to begin a Phase I safety clinical trial for ... cells. This multicenter Phase I safety trial will enroll ... injury patients, with an American Spinal Injury Association (ASIA) ...
... and emotional problems a year after surgery than before their ... key findings of a research study of more than 400 ... . Researchers from The Netherlands spoke to 216 ... who had undergone planned surgery, ranging from plastic surgery to ...
... new surge of scientific research has uncovered telltale signs ... and spinal taps, many questions remain unanswered about the ... of patient care, according to Dr. Kenneth S. Kosik, ... California and co-director of UCSB,s Neuroscience Research Institute. ...
... Massachusetts Medical School have identified a novel approach ... decrease the recurrence of glioblastoma multiforme, the most ... horrendous tumors, and new therapies are desperately needed," ... of biochemistry and molecular pharmacology at the University ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... in cleaning up a massive oil spill off the northwest ... health problems facing workers involved in the recent Deepwater ... the Aug. 24 online issue of the Annals of ...
Cached Medicine News:Health News:Biosynthetic Corneas Show Promise in Transplants 2Health News:Biosynthetic Corneas Show Promise in Transplants 3Health News:Neuralstem files FDA application for first chronic spinal cord injury stem cell trial 2Health News:Neuralstem files FDA application for first chronic spinal cord injury stem cell trial 3Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Are early testing and drug development the most pressing issues in Alzheimer's care? 2Health News:Double-therapy approach effectively inhibited brain cancer recurrence 2Health News:2002 Oil Spill May Shed Light on Health Problems for Deepwater Workers 2Health News:2002 Oil Spill May Shed Light on Health Problems for Deepwater Workers 3
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
... The Ruggles Retractor System, a ... and the versatility of two systems ... hands from the surgical site during ... accurate retractor insertion. The retractor body ...
Fortitude as a unique complement to the spinal concepts family of products....
Medicine Products: